Navigation Links
Vanda Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:2/14/2008

ceuticals Inc. is a biopharmaceutical company focused on the development and commercialization of clinical-stage product candidates for central nervous system disorders. The company has three product candidates. Vanda's lead product candidate, Fiapta(TM) (iloperidone), is a compound for the treatment of schizophrenia and bipolar disorder, for which Vanda has recently submitted an NDA to the FDA. Vanda's second product candidate, VEC-162, is a compound for the treatment of sleep and mood disorders, which is currently in Phase III for chronic insomnia. Vanda's third product candidate, VSF-173, is a compound for the treatment of excessive sleepiness in Phase II. For more on Vanda Pharmaceuticals Inc., please visit http://www.vandapharma.com.

NOTE REGARDING FORWARD-LOOKING STATEMENTS

This release contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, including statements regarding Vanda's plans for its product candidates. Words such as, but not limited to, "look forward to," "believe," "expect," "anticipate," "estimate," "intend," "plan," "targets," "likely," "will," "would," "should," and "could," and similar expressions or words identify forward-looking statements. Such forward-looking statements are based upon current expectations that involve risks, changes in circumstances, assumptions and uncertainties. Vanda is at an early stage of development and may not ever have any products that generate significant revenue. Important factors that could cause actual results to differ materially from those reflected in Vanda's forward-looking statements include, among others, a failure of Vanda's product candidates to be demonstrably safe and effective, a failure to obtain regulatory approval for the company's products or to comply with ongoing regulatory requirements, a lack of acceptance of Vanda's product candidates in the marketplace, a fa
'/>"/>

SOURCE Vanda Pharmaceuticals Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Vion Pharmaceuticals Holds Special Meeting of Stockholders
2. Jazz Pharmaceuticals, Inc. Announces Fourth Quarter and Full Year 2007 Financial Results
3. Cellegy Pharmaceuticals Announces Signing of Definitive Merger Agreement
4. Peregrine Pharmaceuticals Doses First Patient in Phase II Clinical Trial of Bavituximab in Patients With Advanced Breast Cancer
5. Peregrine Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
6. Access Pharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
7. XTL Biopharmaceuticals to Present at the 10th Annual BIO CEO & Investor Conference
8. Koronis Pharmaceuticals Appoints David Drajeske Director of Business Development
9. Onyx Pharmaceuticals to Present at BIO CEO & Investor Conference
10. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
11. Meditrina Pharmaceuticals, Inc. Announces Exclusive Global License Agreement With AstraZeneca
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2015)... May 05, 2015 VetStem Biopharma, ... Animal Health, Jeffrey Schaffer, DVM, as Director of ... 15 years of experience in the veterinary regenerative ... addition to our veterinarian lead organization”. Dr. ... “Dr. Schaffer will be responsible for all technical ...
(Date:5/5/2015)... May 05, 2015 Research and Markets ... the addition of the "Separation Systems ... offering. Macromolecules which include protein, ... or are broken into smaller molecules, during ... separation requires various advanced systems like centrifugation, ...
(Date:5/5/2015)... TEL AVIV, Israel , May 5, 2015 ... that the Company was approved to continue trading ... companies. OTCQB Marketplace allows for ... an electronic broker-dealers. Investors can have real-time quotes ... The OTCQB Marketplace includes ...
(Date:5/5/2015)... , May 5, 2015  Renova™ Therapeutics, ... congestive heart failure and other chronic diseases, has ... independent analysis designed to reflect the healthcare patterns ... This model will be used to characterize the ... could have on those groups of patients and ...
Breaking Biology Technology:Leading Regenerative Veterinary Medicine Company, VetStem Biopharma announces the addition of Dr Jeffrey Schaffer as the Director of Veterinary Professional Services. 2Global Separation Systems Market in Biotechnology 2015-2019 - Trends and Forecasts for the $28 Billion Market 2Tikcro Technologies Announces Approval to Continue Trading on OTCQB 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 2RAND Health Advisory Services modeling heart failure patient outcomes to inform potential impact of Renova Therapeutics lead product candidate 3
... , , , ... Inc. today announced that it completed the initial closing ... proceeds will be used primarily to support the company,s ... therapy designed to reestablish healthy vasculature following common interventions ...
... DENVER, Colorado and JERUSALEM, September ... Joint Venture announced today,that Children,s Hospital is enrolling patients ... a series of cord blood transplant sites,worldwide, five of ... U.S., Spain, Italy, Hungary and Israel. The trial is ...
... Creating ... becomes increasingly difficult when a self detonating molecule is involved. WeylChem Corporation overcame this ... with the iC Safety™ software module. That,s how they avoided any process risks. ... Columbia, MD (PRWEB) ...
Cached Biology Technology:Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 2Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 3Pervasis Therapeutics Announces $17 Million in Financing and New Board Member 4Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 2Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 3Children's Hospital in Colorado Rounds off List of 24 Cord Blood Transplant Centers Worldwide Enrolling for ExCell Trial Studying StemEx(R) for Leukemia and Lymphoma 4WeylChem Avoids Process Safety and Thermal Hazard Analysis Risks by Studying Heat Generation at the Click of one Button 2WeylChem Avoids Process Safety and Thermal Hazard Analysis Risks by Studying Heat Generation at the Click of one Button 3
(Date:4/27/2015)... Apr. 27, 2015 NXT-ID, Inc. (NASDAQ: ... company focused on the growing mobile commerce market, announces ... pre-order customers the first week of May, 2015 and ... of May. Gino Pereira , ... for the company as Wocket® enters the consumer market. ...
(Date:4/20/2015)... 2015 The announcement comes as ... Records Management (GRM), Ireland,s foremost records ... Having built up an impressive track record of clients within ... within the records management sector in Dubai ... GCC staffbase and employ a further eight staff members at ...
(Date:4/13/2015)... , April 13, 2015 ... Research, "Global Biometrics Market Forecast & Opportunities, 2020", the ... CAGR of around 14% till 2020. The biometrics ... large scale implementation and review of biometric management ... of new products with greater efficiency, are resulting ...
Breaking Biology News(10 mins):Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 2Wocket, the Smartest Wallet You Will Ever Own, Announces Shipment to Pre-order Customers 3Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 2Glenbeigh Records Management Wins Contract With Dubai Islamic Bank 3Global Biometrics Market to Cross US$ 21 Billion by 2020: TechSci Research 2
... technology commercialization, entrepreneurship RUSTON, La. Louisiana Tech ... from the Economic Development Administration (EDA) for establishing ... to support and expedite the introduction of new ... and the nation. LA_i6, to be operated ...
... remained constant through more than 400 million years of evolution, ... September 29, 2011, online version of the journal Immunity, ... to function even when pieces of shark, frog and trout ... depends on a few crucial amino acids, found also in ...
... Love-sick and lonely, the male girded his loins and took immediate ... as a U of T Mississauga professor discovered. The ... became so enamored with a brown "stubby" beer bottle that he ... trying to copulate in the hot sun rather than leave willingly, ...
Cached Biology News:Louisiana Tech University receives $1.1 million EDA grant to support 'green' innovations 2Louisiana Tech University receives $1.1 million EDA grant to support 'green' innovations 3Humans and sharks share immune system feature 2Humans and sharks share immune system feature 3University of Toronto Mississauga professor wins Ig Nobel Prize for beer, sex research 2
... S2 cells are used for heterologous protein ... (DES). The S2 cell line was derived ... hours old) Drosophila melanogaster embryos (1). ... room temperature without CO2 and is easily adapted ...
... syringe pump series combines Harvard Apparatuss best pump ... a wide range of configuration options. A lookup ... of syringes from all the major manufacturers. A ... the pertinent information from across the lab. All ...
... For our novel expression vectors, we in-troduced ... dual controls: (i) at tran-scriptional level at the ... replication level by amplifying the plasmid copy number, ... is that it retains practically all of the ...
... This CLS number is a new ... product number. If showing no availability yet, ... (C6421) or contact customer service for assistance. ... Comp Dim: surface area 21 cm ...
Biology Products: